New stem cell approach aims to boost immune attack on tough childhood cancers
NCT ID NCT06625190
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This study tests a stem cell transplant that removes certain immune cells (alpha/beta T cells and CD19+ B cells) and adds a drug called zoledronic acid to help the donor cells fight solid tumors that have come back or not responded to treatment. It includes children and young adults aged 6 months to 25 years with cancers like neuroblastoma, sarcoma, and others. The goal is to see if this approach is safe and improves survival by enhancing the graft-versus-tumor effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.